This continuing medical education activity is supported through educational grant from Genentech, a member of the Roche Group.

Learning Objectives

Upon completion of this activity, the participant should be able to:

Describe the differences in real-world clinical outcomes with those from prospective clinical trials.
Develop individualized treatment regimens for patients with AMD who may benefit from treatments with longer duration.
Discuss newer compounds in development or recently approved that are designed to improve visual outcomes while decreasing treatment burden.

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:

Internet Explorer 11 for Windows

Edge (recent versions; Chromium-based) for Windows

Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:

4GB+ RAM

Recommended internet speed 5Mbps+

Faculty and Disclosures

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno School of Medicine
Reno, Nevada

Carl D. Regillo, MD
Professor of Ophthalmology
Thomas Jefferson University
Director, The Retina Service of Wills Eye Hospital
Partner, Mid Atlantic Retina
Philadelphia, Pennsylvania

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Arshad M. Khanani, MD, MA; and or spouse; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerpio, Allegro, Allergan, Graybug, Genentech, Gyroscope, Kodiak, Notal Vision, Novartis, Opthea, Orbit BioMedical, Oxurion, Polyphotonix, Recens Medical, and Regenexbio. Grant/Research Support: Advernum, Aerpio, Allergan, Gemini, Genentech, Graybug, Gyroscope, Kodiak, Novartis, Opthea, Oxurion, Recens Medical, and Regenxbio. Speaker’s Bureau: Allergan, Genentech, and Novartis.

Carl Regillo, MD, and/or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Advernum, Allergan, Chengdu Kanghing, Eyepoint, Genentech, Graybug Vision, IVERIC bio, Kodiak Sciences, Merck, Novartis, and Opthea. Grant/Research Support: Advernum, Allergan, Genentech, Gemini Therapeutics, Gyroscope Therapeutics, IVERIC bio, Kodiak Sciences, Novartis, Opthea, Regeneron Pharmaceuticals, and Regenxbio.

The staff and planners at Evolve Medical Education have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech.

Forget your password?

Pretest

1. Please rate your confidence in your ability manage patients with neovascular age-related macular degeneration(nAMD)(based on a scale of 1 to 5, with 1 being not at all confident and 5 being extremely confident).*
a. 1 b. 2 c. 3 d. 4 e. 5
2. According to the clinical trial data, what proportion of patients receiving intravitreal anti-VEGFtherapy require frequent (every 8 weeks or less) treatment?*
- a. 1/3
- b. 2/3
- c. 1/4
- d. 1/2
3. According to the LADDER study, how long did was drug delivery sustained through the port delivery system in the high concentration group?*
- a. 3 months
- b. 6 months
- c. 9 months
- d. Longer than 1year
4. According to the LADDER and ARCHWAY studies, what percent of patients developed vitreous hemorrhage with insertion of the port delivery system when photocoagulation was used?*
- a. 5%
- b. 10%
- c. 15%
- d. 20%
5. All of the following steps are important for implantation of the port delivery system except:*
- a. Adequate uveal coagulation
- b. Precise wound size
- c. No tenons closure
- d. Adequateconjunctiva and tenons closure
6. An 81-year-oldman receives ranibizumab injections every 4 weeks for nAMD. He is having difficulty maintaining his office visit schedule and asks about other options. Which of the following is a reasonable option for this patient?*
- a. Stop ranibizumab therapy
- b. Explain the port delivery system and reassure the patient this therapy may become available soon
- c. Start bevacizumab therapy
- d. Start aflibercepttherapy

Video Resources

Instructions

Step 1 of 2

1. Based on this activity, please rate your confidence in your ability manage patients with neovascular age-related macular degeneration(nAMD)(based on a scale of 1 to 5, with 1 being not at all confident and 5 being extremely confident).*
a. 1 b. 2 c. 3 d. 4 e. 5
2. According to the clinical trial data, what proportion of patients receiving intravitreal anti-VEGFtherapy require frequent (every 8 weeks or less) treatment?*
- a. 1/3
- b. 2/3
- c. 1/4
- d. 1/2
3. According to the LADDER study, how long did was drug delivery sustained through the port delivery system in the high concentration group?*
- a. 3 months
- b. 6 months
- c. 9 months
- d. Longer than 1year
4. According to the LADDER and ARCHWAY studies, what percent of patients developed vitreous hemorrhage with insertion of the port delivery system when photocoagulation was used?*
- a. 5%
- b. 10%
- c. 15%
- d. 20%
5. All of the following steps are important for implantation of the port delivery system except:*
- a. Adequate uveal coagulation
- b. Precise wound size
- c. No tenons closure
- d. Adequateconjunctiva and tenons closure
6. An 81-year-oldman receives ranibizumab injections every 4 weeks for nAMD. He is having difficulty maintaining his office visit schedule and asks about other options. Which of the following is a reasonable option for this patient?*
- a. Stop ranibizumab therapy
- b. Explain the port delivery system and reassure the patient this therapy may become available soon
- c. Start bevacizumab therapy
- d. Start aflibercepttherapy
Profession:*
- MD/DO
- NP
- Nurse/APN
- PA
- OD
- Other
Years in Practice:*
- >20
- 11-20
- 6-10
- 1-5
- <1
Patients Seen Per Week ( with the disease targeted in this activity):*
- 0
- 1-15
- 16-30
- 31-50
- 50+
Region:*
- Northeast
- Northwest
- Midwest
- Southeast
- Southwest
Setting:*
- Solo Practice
- Community Hospital
- Government or VA
- Group Practice
- Other
- I do not actively practice
Models of Care:*
- Fee for Service
- ACO
- Patient-Centered Medical Home
- Capitation
- Bundled Payments
- Other

Did the program meet the following educational objectives?*

	Agree	Neutral	Disagree
Describe the differences in real-world clinical outcomes with those from prospective clinical trials.
Develop individualized treatment regimens for patients with AMD who may benefit from treatments with longer duration.
Discuss newer compounds in development or recently approved that are designed to improve visual outcomes while decreasing treatment burden.

	Yes	No
The design of the program was effective for the content conveyed
The content supported the identified learning objectives
The content was free of commercial bias
The content was relative to your practice
The faculty was effective
You were satisfied overall with the activity
Would you recommend this program to your colleagues

Specialty

Course Type

Specialty

Course Type

Search

Menu

Specialty

Course Type

Search

Menu

Sustained Delivery of Anti-VEGF Agents: Surgical Videos Highlighting Key Techniques

Webinar Credits: .75

Expiration Date: Thursday, September 30, 2021

Release Date: September 2020

Learning Objectives

Accreditation and Designation Statement

Participation Method

Faculty and Disclosures

Disclaimer

Pretest

Video Resources

Test

Instructions

Step 1 of 2

Sustained Delivery of Anti-VEGF Agents: Surgical Videos Highlighting Key Techniques

Webinar Credits: .75

Expiration Date: Thursday, September 30, 2021

Release Date: September 2020

Learning Objectives

Accreditation and Designation Statement

Participation Method

Faculty and Disclosures

Disclaimer

Please log in to view this course

Pretest

Video Resources

Test

Instructions

Step 1 of 2